In vitro and in vivo models have suggested that a new antibody-drug-conjugate named anetumab ravtansine that targets mesothelin could be a potential targeted therapy for the treatment of thymic carcinoma [98]. This evidence concerns the gene MSLN and thymic carcinoma.